mTOR Inhibition for Cancer Therapy: Past, Present and Future (Paperback, Softcover reprint of the original 1st ed. 2016)

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

General

Imprint:	Springer Editions
Country of origin:	France
Release date:	August 2016
First published:	2016
Editors:	Monica Mita • Alain Mita • Eric K. Rowinsky
Dimensions:	235 x 155mm (L x W)
Format:	Paperback
Pages:	300
Edition:	Softcover reprint of the original 1st ed. 2016
ISBN-13:	978-2-8178-0557-3
Categories:	Books > Medicine > Clinical & internal medicine > Haematology Books > Medicine > General issues > Medical equipment & techniques > Medical research Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General Promotions
LSN:	2-8178-0557-7
Barcode:	9782817805573

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!